[artículo] 
inThe American Journal of Psychiatry > Año 2022 - Vol. 179 - No.7 (Julio) . - pp. 490-499

Título :	Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder : a randomized double-blind controlled trial
Tipo de documento:	texto impreso
Autores:	Herriot Tabuteau, Autor ; Amanda Jones, Autor ; Ashley Anderson, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 490-499
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Trastorno depresivo mayor, Dextrometorfano, Bupropión
Resumen:	Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder.
Link:	./index.php?lvl=notice_display&id=28583

[artículo] Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder : a randomized double-blind controlled trial [texto impreso] / Herriot Tabuteau, Autor ; Amanda Jones, Autor ; Ashley Anderson, Autor . - 2022 . - pp. 490-499.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No.7 (Julio) . - pp. 490-499

Palabras clave:	Trastorno depresivo mayor, Dextrometorfano, Bupropión
Resumen:	Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder.
Link:	./index.php?lvl=notice_display&id=28583